• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

RIDSTRESS RCT Results: Can Sildenafil Reduce Emergency Operative Births for Fetal Compromise?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • There are currently no interventions for nonreassuring fetal status aside from delivery if unresolved
  • In this phase II clinical trial, Turner et al. (AJOG, 2020) examined whether sildenafil citrate could be used to reduce the number of emergency operative births for fetal compromise

METHODS:

  • Phase II double-blind randomized controlled trial (RCT)
    • RIDSTRESS (“Reducing the Incidence of Fetal Distress with Sildenafil Citrate”) trial
  • Participants
    • 18 to 50 years of age
    • Term pregnancy (≥37 weeks)
    • In early labor (cervical dilation <4cm) or undergoing scheduled induction of labor
  • Exclusion criteria
    • Preeclampsia or on antihypertensive medication | >1 previous cesarean | SGA | Contraindication to sildenafil
  • Interventions
    • Sildenafil citrate group
      • 50 mg of sildenafil citrate orally every 8 hours up to 150 mg
    • Control group
      • Placebo
  • Study design
    • Intrapartum fetal monitoring (based on RANZCOG guidelines)
    • Analysis was by intention-to-treat
  • Primary outcomes
    • Emergency operative birth for intrapartum fetal compromise
      • Either by cesarean or instrumental vaginal birth
    • Mean indices of fetal and uteroplacental perfusion using Doppler ultrasound
  • Statistical analysis
    • 288 women per group (>90% power, alpha of 0.05) to demonstrate 50% change in primary outcome | 320 per group needed to account for 10% potential drop out rate

RESULTS:

  • 300 women were randomized
    • Sildenafil citrate: 150 women
    • Control: 150 women
  • Sildenafil citrate reduced the risk of emergency operative birth (p=0.0004)
    • Sildenafil citrate: 18%
    • Control: 36.7%
    • Relative risk (RR) 0.49 (95% CI, 0.33 to 0.73)
    • Number needed to treat: 5 (95% CI, 3 to 11)
  • Sildenafil citrate reduced the risk of meconium-stained liquor or pathologic fetal heart rate patterns (p=0.0005)
    • Sildenafil citrate: 25.3%
    • Control: 44.7%
    • RR 0.57 (95% CI 0.41 to 0.79)
  • Evidence for the following effects was found to be inconclusive
    • Fetal scalp sampling rates (p=0.06)
      • Sildenafil citrate: 2.0%
      • Control: 6.7%
      • RR 0.30 (95% CI, 0.08 to 1.07)
    • Adverse neonatal outcome (p=0.89)
      • Sildenafil citrate: 20.7%
      • Control: 21.3%
      • RR 0.97 (95% CI 0.62 to 1.50)
  • Cord blood levels of sildenafil citrate (or metabolite): 3.6% of maternal level
  • No significant differences detected for
    • Maternal adverse events
    • Indices of fetal and uteroplacental perfusion (only studied in 71 women)

CONCLUSION:

  • In this phase II trial, sildenafil citrate
    • Reduced the risk of emergency operative birth by 51%
    • Reduced the risk of meconium-stained liquor or pathologic fetal heart rate patterns by 43%
  • However, results were inconclusive for adverse and other outcomes, so while promising, authors acknowledge that larger phase III trials are necessary sildenafil citrate can be used clinically

Learn More – Primary Sources:

Safety and efficacy of sildenafil citrate to reduce operative birth for intrapartum fetal compromise at term: a phase 2 randomized controlled trial

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Try it Free  »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Can Sildenafil Citrate Help in the Management of Oligohydramnios?
Forceps/Vacuum Delivery vs Cesarean Section and Adverse Maternal and Perinatal Outcomes
ANODE RCT Results: Antibiotic Prophylaxis for Forceps or Vacuum Extraction?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site